Biochips under COVID-19:a new stage of well-grounded development and accelerated translation  

COVID-19背景下生物芯片进入稳步发展与快速转化的新阶段

作　　者：Jiajia Liu Youchun Xu Jing Cheng 刘佳佳;徐友春;程京(State Key Laboratory of Membrane Biology,Department of Biomedical Engineering,School of Medicine,Tsinghua University,Beijing 100084,China;National Engineering Research Center for Beijing Biochip Technology,Beijing 102200,China)

机构地区：[1]State Key Laboratory of Membrane Biology,Department of Biomedical Engineering,School of Medicine,Tsinghua University,Beijing 100084,China [2]National Engineering Research Center for Beijing Biochip Technology,Beijing 102200,China

出　　处：《Science Bulletin》2022年第18期1823-1826,共4页科学通报（英文版）

基　　金：supported by the National Natural Science Foundation of China(31870853 and 82161138004);Guangzhou Institute of Respiratory Health Open Project(funds provided by China Evergrande Group,2020GIRHHMS02);Emergency Key Program of Guangzhou Laboratory(EKPG21-14);Tsinghua University Spring Breeze Fund(20201080532);Beijing Nova Program 2020,and Beijing Lab Foundation。

摘　　要：Severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)has placed a heavy burden on the global healthcare system,especially in developing and underdeveloped countries where professionals and specialized laboratories are scarce.And due to the increased demand for large-scale detection and the shortage of animal models for vaccines and antiviral drugs under the coronavirus disease 2019(COVID-19)pandemic.

关 键 词：生物芯片 DRUGS ACUTE 

分 类 号：R440[医药卫生—诊断学] TN40[医药卫生—临床医学]